Stem cell therapy shows promise for common cause of blindness

November 14, 2017

Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients' vision.

In both studies, researchers turned into a type of retinal support cell, called retinal pigment epithelial (RPE) cells, and injected them into the eyes of people suffering from dry age-related macular degeneration (AMD), a leading cause of new blindness in people over age 55. There is currently no treatment available for this disease affecting 30 million people worldwide, though nutritional supplements can be protective.

In a healthy retina, RPE cells provide supportive functions such as nutrition and waste management for photoreceptors, the cells that process light, allowing us to see. Dysfunction and degeneration of RPE cells are part of the process that leads to visual loss in . The human embryonic stem cell-derived RPE cells injected under the retina are designed to support and/or replace the patient's failing RPE cells.

Experts in regenerative medicine believe that will be one of the first areas of success with stem-cell therapy. This is because it is relatively easy to grow large numbers of RPE cells in the lab. These cells are nearly identical to those in the eye. RPE cells do not require formation of neuronal connections to support the photoreceptors within the retina. Also, the location in the eye in which the cells are transplanted is recognized as an immune-privileged site, meaning it's one of the very few sites in the body in which the risk of rejection of the is low. Lastly, the treatment can be accomplished with a small number of cells in a very localized area, reducing the risks.

The researchers from Hadassah-Hebrew University Medical Center in Jerusalem, Israel, conducted studies designed to test the safety of the procedure in human subjects. They injected a suspension of either 50,000 or 200,000 RPE cells derived from human embryonic stem cells underneath the patients' retina. The surgical procedure was well-tolerated. Within a few weeks, they could see signs that the retina was healing at the injection site, and images of the back of the eye suggest the possibility that the transplanted RPE cells survived. Patients' vision remained largely stable throughout the study, and they suffered no unexpected side effects.

"We're encouraged by the results thus far," said Eyal Banin, M.D., Ph.D., lead investigator and one of the developers of the technology. "But this is just a first step in the long road towards making regenerative cell therapy a reality in macular and retinal degeneration."

An additional trial site for this stem cell treatment is expected to open soon in the United States.

A second research group from Bascom Palmer Eye Institute in Miami has conducted two studies using RPE cells derived from human embryonic stem cells to treat patients with dry AMD, as well as patients with a different form of called Stargardt disease. It's the most common form of inherited juvenile AMD. Like dry AMD, there is no treatment available for this blinding disease.

Stem cells implanted in these patients survived for up to three years, and there were no side effects. Some of these patients even gained vision.

"RPE cells appear to be well tolerated in the human eyes," said lead researcher Ninel Z. Gregori M.D., of Bascom Palmer Eye Institute. "There were no serious adverse events attributable to the transplanted RPE cells, including no tumor formation. "This study supports further development of human embryonic stem cell-derived RPE for degenerative diseases of the macula."

Explore further: Study suggests stem cells may repair dying retinal cells

Related Stories

Study suggests stem cells may repair dying retinal cells

January 21, 2016
Researchers at St. Erik Eye Hospital and Karolinska Institutet have for the first time successfully transplanted human retinal pigment epithelial cells derived from stem cells into eyes that are similar to human eyes. The ...

New model for hard-to-study form of blindness paves way for future research

September 6, 2017
Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab. A study published in the Proceedings of the National ...

Stem cell injection may soon reverse vision loss due to age-related macular degeneration

April 14, 2015
An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai. Currently, there is no treatment that ...

First embryonic stem cell therapy safety trial in Asian patients

April 30, 2015
A clinical trial in the Republic of Korea for patients with degenerative eye diseases is the first to test the safety of an embryonic stem cell therapy for people of Asian descent. The study, which followed four individuals ...

Stem cell therapy reverses blindness in animals with end-stage retinal degeneration

January 10, 2017
A stem cell-based transplantation approach that restores vision in blind mice moves closer to being tested in patients with end-stage retinal degeneration, according to a study published January 10 in Stem Cell Reports. The ...

Stem cells improve visual function in blind mice

October 1, 2012
An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers.

Recommended for you

Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops ...

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Exploring the genetics of glaucoma and retinal development

November 10, 2017
Guillermo Oliver, PhD, the Thomas D. Spies Professor of Lymphatic Metabolism, recently published two studies related to the eye, one on retinal formation and the other on the genetics behind glaucoma.

Scientists discover potential treatment to stop glaucoma in its tracks

November 6, 2017
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.